Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) is a clinical stage biopharmaceutical company that regularly issues news about its precision oncology pipeline and Generative Phosphoproteomics AP3 platform. Company announcements describe progress for its lead CHK1/CHK2 inhibitor ACR-368 in a registrational-intent Phase 2 or Phase 2b trial in endometrial cancer, as well as updates on ACR-2316, a WEE1/PKMYT1 inhibitor in Phase 1 development, and AP3-enabled preclinical programs such as the CDK11-targeting candidate ACR-6840.
News releases from Acrivon often cover interim clinical data, including response rates and tumor shrinkage in AP3-prioritized solid tumor types, details on dose-escalation cohorts, and observations of drug target engagement based on AP3 profiling. The company also reports on regulatory designations, such as FDA Fast Track status for ACR-368 monotherapy in endometrial cancer and FDA Breakthrough Device designation for the ACR-368 OncoSignature assay, as well as trial design elements like biomarker-selected and biomarker-unselected arms and combinations with ultra-low dose gemcitabine.
Investors and observers following ACRV news can expect updates on Acrivon’s presentations at scientific conferences, including AACR and AACR-NCI-EORTC, where the company highlights AP3-based mechanistic data, the AP3 KaiSR generative AI model, and pharmacodynamic insights for ACR-2316 and other candidates. The company also issues periodic financial results and business highlights, summarizing cash resources, research and development activities, and anticipated clinical and regulatory milestones for its AP3-enabled pipeline.
This ACRV news page aggregates these press releases and related coverage, providing a centralized view of Acrivon’s reported clinical progress, platform developments, and corporate updates over time.
Acrivon Therapeutics (Nasdaq: ACRV) reported third-quarter 2025 results and program updates on Nov 13, 2025. Key highlights include continued advancement of a registrational-intent Phase 2b trial of ACR-368 in recurrent high-grade endometrial cancer, an arm testing ultra-low dose gemcitabine without pre-treatment biopsy, and ongoing dosing in the Phase 1 dose-escalation study of ACR-2316 with reported tumor shrinkage and a confirmed partial response.
Financials: Net loss $18.2M in Q3 2025 versus $22.4M year-ago; R&D $13.6M versus $18.9M; cash and investments $134.4M as of Sept 30, 2025, expected to fund operations into Q2 2027. The company also presented AP3/KaiSR platform and preclinical efficacy data at AACR-NCI-EORTC.
Acrivon Therapeutics (NASDAQ: ACRV) will present three posters at the AACR-NCI-EORTC International Conference (Oct 22-26, 2025) highlighting its Generative Phosphoproteomics AP3 platform and AP3 KaiSR ensemble model.
Preclinical data for ACR-2316 show differentiated and superior pathway effects versus benchmark WEE1 and PKMYT1 inhibitors, with analyses indicating a critical role for PLK1 in ACR-2316’s activity. The company said it will report initial Phase 1 clinical data for ACR-2316 later in 2025 and disclosed clinical activity including a confirmed partial response observed during dose escalation.
Posters will be available on Acrivon’s website shortly after presentation.
Acrivon Therapeutics (Nasdaq: ACRV), a clinical stage biotech company focused on precision medicines, has announced an inducement grant under Nasdaq Rule 5635(c)(4). The company approved stock options for 225,000 shares to one employee, with an exercise price equal to ACRV's closing price on October 1, 2025.
The options will vest 25% after one year from employment start date, followed by 2.083% monthly installments thereafter, contingent on continued employment. The grant was approved by Acrivon's Board as a material inducement to employment.
[]Acrivon Therapeutics (Nasdaq: ACRV) reported Q2 2025 financial results and business updates, highlighting progress in its clinical-stage assets. The company's lead drug ACR-368 is advancing in a registrational-intent Phase 2 study for endometrial cancer, showing promising responses in patients who progressed after chemotherapy and anti-PD1 therapy. Their second asset, ACR-2316, demonstrated initial clinical activity in Phase 1 trials, including a confirmed partial response in endometrial cancer.
The company reported a net loss of $21.0 million for Q2 2025, with R&D expenses of $16.2 million. Acrivon maintains a strong financial position with $147.6 million in cash and equivalents, expected to fund operations into Q2 2027. Key upcoming milestones include updates on the ACR-368 registrational-intent trial and initial clinical data from ACR-2316's Phase 1 study in H2 2025.
Acrivon Therapeutics (NASDAQ: ACRV) announced upcoming data presentation at AACR Annual Meeting 2025 regarding their clinical-stage drug candidate ACR-2316, a selective WEE1/PKMYT1 inhibitor. The Phase 1 trial is progressing ahead of schedule, with three dose-escalation cohorts completed without safety concerns.
Key highlights include:
- ~25% RECIST tumor shrinkage observed at dose level 3
- Drug target engagement confirmed at dose levels 1 and 2
- No dose-limiting toxicities reported
- Currently enrolling dose level 4
The presentation will reveal how ACR-2316, developed using their AP3 Generative Phosphoproteomic platform, induces mitotic and replicative tumor cell death. The drug has shown superior anti-cancer activity in preclinical studies compared to benchmark inhibitors.
Acrivon Therapeutics (Nasdaq: ACRV) has appointed Dr. Mansoor Raza Mirza as Chief Medical Officer, effective April 9, 2025, replacing Jean-Marie Cuillerot. Dr. Mirza, a world-renowned oncology expert specializing in gynecologic malignancies, will lead clinical development including the ongoing ACR-368 Phase 2b registrational-intent trial in endometrial cancer and the ACR-2316 Phase 1 study in solid tumors.
Dr. Mirza joins from Copenhagen University National Medical Center, where he served as chief oncologist. He has authored seven articles in the New England Journal of Medicine and led numerous successful trials, including those leading to approvals of Zejula for ovarian cancer and a new frontline therapy for endometrial cancer combining platinum-based chemotherapy with anti-PD-1 checkpoint inhibitor.
Acrivon Therapeutics (NASDAQ: ACRV) reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical programs. The company's ACR-368 showed promising results in endometrial cancer patients, achieving a 35% confirmed overall response rate in OncoSignature-positive patients who had previously progressed on anti-PD-1 and chemotherapy.
Key clinical highlights include a 50% response rate in relapsed patients with duration of response exceeding 10 months, and 33% response rate in refractory patients. The Phase 1 trial of ACR-2316 is ahead of schedule, with initial clinical activity observed. The company has prioritized endometrial cancer development while deprioritizing ovarian and bladder cancer programs.
Financial results show a net loss of $22.8 million for Q4 2024 and $80.6 million for the full year. With $184.6 million in cash and investments as of December 31, 2024, Acrivon expects to fund operations into 2027.
Acrivon Therapeutics (Nasdaq: ACRV) has announced a virtual R&D event scheduled for March 25, 2025, from 4:00 p.m. to 5:15 p.m. ET. The event will showcase the company's Generative Phosphoproteomics AP3 platform capabilities and provide updates on two key clinical programs:
- Phase 2b study of ACR-368
- Phase 1 study of ACR-2316
The event will feature presentations from Acrivon's leadership team and distinguished key opinion leaders in endometrial cancer, including:
- Dr. Mansoor Raza Mirza, chief oncologist at Copenhagen University Hospital
- Dr. Robert L. Coleman, co-director of the Gynecologic Oncology Group Partners Foundation
- Dr. Jesper Olsen, professor at the University of Copenhagen
A live webcast will be accessible through the company's investor relations website and will remain available for at least 30 days after the event.
Acrivon Therapeutics (ACRV) announces FDA Breakthrough Device designation for its ACR-368 OncoSignature assay in endometrial cancer. This multiplex immunofluorescence assay is designed to identify patients likely to respond to ACR-368 treatment, currently in a registrational-intent Phase 2b trial.
The company's clinical data at ESMO 2024 showed a confirmed overall response rate of 62.5% and demonstrated significant segregation between biomarker-positive and negative patient groups (p=0.009). The assay was developed using their AP3 (Acrivon Predictive Precision Proteomics) platform, which combines generative AI for drug design and indication finding.
Market research indicates strong interest in ACR-368's clinical profile, with an estimated 30,000 annual cases of high-grade, locally advanced or metastatic, recurrent endometrial cancer in the U.S.